Your browser is no longer supported. Please, upgrade your browser.
Savara Inc.
Index- P/E- EPS (ttm)-1.34 Insider Own0.50% Shs Outstand60.29M Perf Week31.62%
Market Cap90.86M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float45.21M Perf Month31.62%
Income-67.60M PEG- EPS next Q-0.10 Inst Own41.50% Short Float1.53% Perf Quarter58.41%
Sales0.30M P/S302.87 EPS this Y-5.70% Inst Trans0.02% Short Ratio2.10 Perf Half Y-8.21%
Book/sh1.27 P/B1.41 EPS next Y37.50% ROA-56.20% Target Price- Perf Year-46.41%
Cash/sh1.86 P/C0.96 EPS next 5Y- ROE-77.40% 52W Range1.00 - 3.59 Perf YTD55.65%
Dividend- P/FCF- EPS past 5Y34.70% ROI- 52W High-50.14% Beta1.17
Dividend %- Quick Ratio12.60 Sales past 5Y- Gross Margin- 52W Low79.86% ATR0.11
Employees36 Current Ratio12.60 Sales Q/Q- Oper. Margin- RSI (14)78.96 Volatility9.91% 6.92%
OptionableYes Debt/Eq0.00 EPS Q/Q38.30% Profit Margin- Rel Volume0.95 Prev Close1.77
ShortableYes LT Debt/Eq0.33 EarningsNov 05 AMC Payout- Avg Volume329.16K Price1.79
Recom2.00 SMA2032.30% SMA5039.13% SMA2002.18% Volume311,962 Change1.13%
Jun-13-19Reiterated H.C. Wainwright Buy $22 → $6
Jun-13-19Downgrade Ladenburg Thalmann Buy → Neutral $21 → $3
Jun-13-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Aug-13-18Resumed ROTH Capital Neutral $12
Jan-03-18Initiated Ladenburg Thalmann Buy $35
Sep-27-17Resumed ROTH Capital Buy $40
Sep-22-17Initiated Jefferies Buy $20
Sep-11-17Initiated JMP Securities Mkt Outperform $20
Jan-21-21 04:24AM  
Dec-10-20 12:02PM  
Nov-24-20 04:15PM  
Nov-11-20 04:05PM  
Nov-05-20 04:20PM  
Sep-11-20 08:05AM  
Sep-09-20 04:05PM  
Sep-08-20 08:05AM  
Sep-04-20 12:47PM  
Sep-03-20 04:05PM  
Aug-25-20 07:42AM  
Aug-06-20 04:02PM  
Aug-05-20 08:05AM  
Jul-30-20 08:05AM  
Jul-05-20 06:11PM  
May-27-20 04:05PM  
May-08-20 08:05AM  
May-07-20 04:05PM  
Apr-30-20 04:05PM  
Apr-15-20 11:26AM  
Apr-02-20 04:05PM  
Mar-30-20 04:05PM  
Mar-23-20 07:53AM  
Mar-12-20 04:05PM  
Mar-11-20 09:23AM  
Mar-05-20 08:05AM  
Jan-16-20 11:21AM  
Jan-06-20 09:14AM  
Jan-02-20 09:30AM  
Dec-30-19 08:05AM  
Dec-20-19 11:51AM  
Dec-19-19 04:18PM  
Dec-03-19 04:05PM  
Nov-27-19 04:05PM  
Nov-26-19 04:05PM  
Nov-18-19 08:05AM  
Nov-15-19 02:45PM  
Nov-13-19 02:45PM  
Nov-12-19 04:05PM  
Nov-11-19 06:15PM  
Nov-07-19 05:50PM  
Oct-31-19 04:05PM  
Oct-17-19 02:45PM  
Oct-15-19 12:42PM  
Oct-11-19 07:15PM  
Oct-07-19 07:30PM  
Oct-03-19 11:00AM  
Oct-02-19 06:00PM  
Sep-18-19 04:15PM  
Sep-02-19 11:39AM  
Aug-08-19 04:02PM  
Jul-31-19 08:02AM  
Jul-15-19 03:49PM  
Jun-25-19 08:52PM  
Jun-20-19 09:45AM  
Jun-19-19 10:29AM  
Jun-13-19 04:02PM  
Jun-12-19 05:48PM  
Jun-10-19 09:03AM  
May-17-19 12:20PM  
May-16-19 11:17AM  
May-15-19 09:00AM  
May-09-19 04:02PM  
May-06-19 08:02AM  
May-02-19 08:02AM  
Apr-09-19 09:00AM  
Apr-02-19 08:00AM  
Apr-01-19 08:00AM  
Mar-13-19 08:52PM  
Mar-12-19 03:18PM  
Mar-06-19 08:00AM  
Mar-04-19 08:00AM  
Feb-06-19 08:00AM  
Jan-16-19 09:29AM  
Dec-21-18 11:18PM  
Dec-19-18 08:00AM  
Nov-16-18 08:00AM  
Nov-07-18 04:02PM  
Nov-01-18 08:00AM  
Oct-31-18 08:00AM  
Oct-15-18 02:09PM  
Sep-27-18 08:00AM  
Aug-09-18 04:03PM  
Aug-02-18 08:00AM  
Jul-26-18 03:49PM  
Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; Phase IIa development stage for treating nontuberculous mycobacterial (NTM) lung infection; and in Phase IIa development stage for the treatment of NTM lung infection in people living with cystic fibrosis. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III development stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elam Nevan CDirectorDec 15Option Exercise0.522,9301,52424,612Dec 17 12:13 PM